

# Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in Nigeria.

Seyi Samson Enitan<sup>1</sup>

<sup>1</sup> Babcock University

**Funding:** The author(s) received no specific funding for this work.

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

## Abstract

**Background:** Vaccination efforts against the Coronavirus Disease 2019 (COVID-19) pandemic may be hampered by vaccine hesitancy. This study assessed the acceptance rate of COVID-19 vaccination at different hypothetical efficacy and safety levels in Nigeria. **Methods:** This web-based study was conducted among a selected Nigerian population between the month of February and May, 2021 using an online self-administered structured questionnaire hosted by Survey Monkey. WhatsApp, Twitter and Facebook were used to disseminate the invitation to take the poll. Data collected were analyzed using Statistical Package for Social Sciences Version 25 with level of significance set at  $P < 0.05$ . **Result:** The finding of this study revealed that a larger proportion of the participants were males (53.9%), within the age group of 31-40 years (25.6%), and earn an average income of less than \$500 per month. Individuals between the ages of 21 and 30 years and 31 to 40 years showed the highest levels of acceptability for the COVID-19 vaccine at 95% efficacy and 5% adverse effects. Older age group (>51 years and above) had the least vaccine acceptance rate (3.3%) at 75% vaccine efficacy and 20% side effect. Respondents who held the belief that vaccinations are essential for their health had higher chance to accept COVID-19 vaccine with OR: 0.76; 95%CI (0.00-0.00), OR: 6.31; 95%CI (0.000-0.000), OR: 1.23; 95%CI (0.193-7.860) and OR: 0.696; 95%CI (0.048-10.047) based on religion, occurrence of diabetes, Pulmonary disease and Hypertension, respectively. **Conclusion:** The results of this research indicate that vaccine acceptance rates are negatively correlated with participants' ages.

**Key Words:** Acceptance, COVID-19, Efficacy, Nigeria, safety, Vaccine.

## INTRODUCTION

The Coronavirus Disease 2019 (COVID-19) which was first identified in December, 2019 by the Chinese health authorities following an outbreak of an epidemic of unusual pneumonia with an unknown etiology in Wuhan, Hubei Province, was caused by the severe acute respiratory syndrome virus 2 (SARS-CoV-2) [1,2]. SARS-CoV-2, like SARS and Middle East Respiratory Syndrome (MERS), most likely began in animals. Spores and droplets in the air disseminate it from person to person. It has rapidly expanded over the globe since its inception [3]. The COVID-19 outbreak has killed a significant number of individuals and has had a significant effect on public health, food security, and the economy. The societal and economic consequences have been disastrous [4]. Around the globe, over 3.3 billion people were at risk of losing their employment, and tens of millions more are at risk of sliding into severe poverty [5]. This has led to difficulties in the medical supply chain, blood transfusion services, and the identification and treatment of chronic disorders [6]. Nigeria, like other African nations, has seen the consequences of the pandemic with more than 188,880 confirmed cases and 2,288 fatalities as of August 26, 2021, according to epidemiological statistics [7]. The epidemic and subsequent border closures have had an impact on Nigeria's food system, economy, and level of poverty [4].

Despite several nations' efforts to restrict travel, keep people separate, and issue recommendations to remain at home, many people have been infected and died due to the COVID-19 pandemic. However, the great majority of individuals on the globe may still get COVID-19, emphasizing the need for an effective vaccination. As COVID-19 becomes a greater concern, a record number of vaccines are being produced [8]. As of December 31, 2020, several vaccination safety and efficacy data have been disclosed [9].

Vaccination programmes has been proposed to likely take a long time to create, depending on how soon clinics can be established and how secure each state's vaccine supply is. In order to estimate the impacts of vaccination and rollout during current outbreaks, a recommended approach in which the vaccine would be given to medical professionals and high-risk patients first, such as those with comorbidities associated with severe COVID-19 [10] and those 65 years and older. This is because those with COVID-19 comorbidities, such as diabetes and hypertension, are 2-4 times more likely to have a serious disease than those who do not have comorbidities. Furthermore, as individuals become older, the severity of their symptoms and their chances of dying swiftly increase [11]. Nations throughout the globe enacted lockdowns and quarantines, erected social barriers, mandated everyone to wear face masks at all times, and placed travel restrictions, because there was no vaccine or viable treatment for COVID-19 at the onset of the pandemic [12].

Consequently, the world economy, as well as people's physical and mental health suffered significantly. Since the COVID-19 pandemic had so many devastating repercussions in so many diverse ways, the worldwide community is working harder than ever to find a solution to prevent future outbreaks. The desire of people to get immunized against an infectious illness is the most important factor influencing the efficiency of vaccination programmes. Refusing to get vaccinated is a major public health issue in poor nations such as Nigeria. People's desire to get vaccinations and faith in the country's immunization programme has declined in the previous ten years as a consequence of vaccine controversies and revelations of vaccines' harmful side effects [13, 14]. A person's choice to get vaccinated is influenced by a range of factors. The Health Belief Model (HBM), which explains and predicts a variety of human behaviours, is one of the most prominent ways for predicting whether a person will get a vaccine [15]. Previous research has shown the accuracy of utilizing HBM structures to predict the number of persons who will get a flu vaccine [16]. The HBM is comprised of several critical components, including signals to act, perceived vulnerability, severity, benefits, and roadblocks [17]. While perceived severity refers to how unwell individuals believe they would feel as a consequence of the illness, perceived susceptibility refers to how probable people believe they will be infected. A person's "perceived benefits" are their ideas about vaccination, but their "perceived obstacles" are their perceptions that vaccination is difficult due to psychological, physical, or economic concerns. Information, people, or events that persuade someone to be vaccinated are referred to as action cues [17].

According to previous research [14, 18, 19], the acceptability of COVID19 vaccinations varies widely around the globe. People's willingness or reluctance to receive the COVID-19 vaccine is heavily influenced by sociodemographic factors such as age, race, occupation, education level, and income, as well as beliefs and attitudes about COVID-19 infection, lack of trust in the government, doubt or mistrust in vaccine safety, employer mandates or recommendations, belief in conspiracy theories, vaccine effectiveness, and the dissemination of false vaccine information [19, 20]. In poor and semi-rich countries, only few studies of this kind have been done [21]. Furthermore, although HICs have a high vaccination rate, low-middle income countries (LMICs) are believed to have a low vaccination rate [22]. Given that vaccination rates remain low in many LMICs, including Nigeria, a developing country. With a greater knowledge of how various vaccine components impact how individuals feel about obtaining a vaccination, public health authorities may be able to identify what type of endorsements, incentives, or messaging are necessary to boost vaccination rates.

## MATERIAL AND METHODS

A self-administered online survey was carried out from February to May of 2021 in Nigeria. The Survey Monkey platform was used to host

the survey. Invitations to do the survey were posted on three social media and instant messaging websites, including Facebook, Twitter, and WhatsApp, in order to find participants. There were various sections in the survey. Information on the study and a page asking for informed consent before participants could proceed with the survey, were included in the first section of the introduction. The questions in the following sections were designed to gather data on socio-demographic traits, current health status, perceptions of COVID-19 risk, impact of the pandemic on the economy, vaccine hesitancy, and attitudes toward social isolation. A few of the questions were taken from earlier research [19, 23, 24]. The survey took between 10 and 15 minutes to finish.

The study's response variable was Nigerians' perceptions of fictitious COVID-19 immunizations with varying degrees of efficiency and safety. A scenario was developed to test people's reactions to the COVID-19 immunization. "Consider that a new COVID-19 vaccine has recently been developed. It has undergone similar testing to the adult flu vaccine. People may choose to receive a free government vaccine." Participants were asked whether they would have a COVID-19 vaccine if it was effective [95%, 75%, or 50% of the time] and had a [5% or 20%] chance of causing adverse effects like rise in temperature or pain in the injection site. There were four possible combinations of vaccination efficacy and danger of adverse effects. Vaccine A was 95% effective with a 20% chance of adverse effects; Vaccine B was 75% effective with a 5% chance of adverse effects; Vaccine C was 75% effective with a 20% chance of adverse effects; and Vaccine D was 50% effective with a 5% chance of adverse effects. Every potential combination has two responses: Yes or No. "Not Sure" was out of the question. Variables that are explicit were collected and considered a variety of plausible reasons for what had occurred. Data on sex, age, location of settlement, religion, nature of occupation, and monthly income, (were collected and classified for statistical purposes. Respondents were also questioned about flu vaccination and COVID-19 comorbid diseases such as hypertension, diabetes, heart difficulties, and lung disorders.

We also enquired about the respondents' experiences with economic disruption by posing two questions: "How much your work changed as a result of the COVID-19 pandemic?" and "How much your salary changed as a result of the COVID-19 pandemic?" The likely responses for the first question were: "No change or not applicable (not working)", "I work fewer hours", "I work more hours" and "I was let go from my job", while for the last question, three possible responses were: "No change", "I am getting paid less", or "I am getting paid more". Additionally, participants' attitude regarding the advantage of vaccination and social exclusion was evaluated.

Five (5) questions from the WHO SAGE Vaccine Hesitancy Scale [25] that are part of the lack of vaccination benefits construct were used to measure vaccine hesitancy: (1) "All routine vaccines recommended by the healthcare workers are beneficial"; (2) "New vaccines carry more risks than older vaccines"; (3) "The information I receive about vaccines from the government is reliable and trustworthy; and (4) "Getting vaccines is a good way to protect me from disease" and (5) "Vaccines are important for my health".

The extent to which the respondents agreed or disagreed with the following three statements was used to gauge their perceptions of the advantages of social isolation: (1) "Social distancing can protect your child or children from COVID-19 (if any)"; (2) "Social distancing can protect your parents from COVID-19"; and (3) "Social distancing can protect you from COVID-19". Each statement had five potential responses: "Strongly agree," "Agree," "Neither agree nor disagree," "Disagree," and "Strongly disagree." The respondent's responses were categorized as "Agree" (those who responded agree or strongly agree), "Neutral" (those who neither agreed nor disagreed), and "Disagree" (those who disagreed and strongly disagreed) for statistical purposes.

## STATISTICAL ANALYSIS

The relevant explanatory factors were identified using a two-step logistic regression for each type of hypothetical COVID-19 vaccination. The odds ratios (ORs), 95% confidence interval (95%CI) and univariate analysis were estimated individually during the initial first phase of


the analysis (*i.e.*, known as crude OR). All explanatory variables with a p-value were calculated in the later step.

## RESULTS

A total of 180 respondents were used for this study of which larger proportion were males 97 (53.9%), within the age group of 31-40 years, 83(46.1%), have an average income of less than \$500 and most of the respondents 163(90.6%) were living in the urban areas (Table 1). Table 2 presents the clinical updates of health status of the subjects. In the table, less than one fifth of the total subjects known their current clinical updates on diabetes, heart disease, pulmonary disease and hypertension even though more than one third (48.9%) of the respondents are health care workers (Figure 1). Determinants associated with COVID-19 vaccine acceptance with respect to socio-demographic of the subjects shows that only religion had significant impact on COVID-19 vaccination at different hypothetical efficacy and safety levels in Nigeria, which is more steeper at 75% vaccine efficacy 20% side effect  $P=0.000(0.000-0.000\text{ CL})$ , categorical variables such as diabetes, Pulmonary disease, Hypertension, wear of face mask and vaccination had significant impact on acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in Nigeria in varying degrees. Respondents who believed vaccinations are essential for their health had higher chance to accept COVID-19 vaccine with OR: 0.76; 50%CI (0.00-0.00), OR: 6.31; 95%CI (0.000-0.000), OR: 1.23; 95%CI (0.193-7.860) and OR: 0.696; 95%CI (0.048-10.047) based on religion, occurrence of diabetes, pulmonary disease and hypertension, respectively (Table 3).

**Table 1.** COVID-19 vaccine acceptance rates according to the sociodemographic characteristic of the study participants (n=180).

Variable	Categories	Total n (%)	95% vaccine efficacy 5% side effect (A)	50% vaccine efficacy 50% side effect (B)	50% vaccine efficacy 5% side effect (C)	75% vaccine efficacy 5% side effect (D)	75% vaccine efficacy 20% side effect (E)
Age group (year)	≤20	31(17.2)	22(12.2)	19(10.6)	23(12.8)	27(15.0)	16(8.9)
	21-30	53(29.4)	38(21.1)	30(16.7)	33(18.3)	43(23.9)	23(12.8)
	31-40	46(25.6)	38(21.1)	19(10.6)	34(18.9)	36(20.0)	19(10.6)
	41-50	38(21.1)	31(17.2)	18(10.0)	27(15.0)	26(14.4)	17(9.4)
	>51	12(6.7)	9(5.0)	8(4.4)	8(4.4)	8(4.4)	6(3.3)
Gender	Female	83(46.1)	59(32.8)	48(26.7)	56(31.1)	65(36.1)	39(21.7)
	Male	97(53.9)	79(43.9)	46(25.6)	69(38.3)	75(41.7)	42(23.3)
Location	Rural	17(9.4)	12(6.7)	9(5.0)	11(6.1)	13(7.2)	6(3.3)
	Urban	163(90.6)	126(70.0)	85(47.2)	114(63.3)	127(70.6)	75(41.7)
Average income	\$1,000-\$1,999 per month	19(10.6)	18(10.0)	12(6.7)	16(8.9)	16(8.9)	8(4.4)
	\$10,000-\$12,999 per month	3(1.7)	1(0.6)	0(0.0)	1(0.6)	2(1.1)	1(0.6)
	\$13,000 per month or more	7(3.9)	7(3.9)	3(1.7)	5(2.8)	4(2.2)	1(0.6)
	\$2,000-\$2,999 per month	24(13.3)	19(10.6)	11(6.1)	17(9.4)	19(10.6)	10(5.6)
	\$3,000-\$4,999 per month	11(6.1)	8(4.4)	8(4.4)	5(2.8)	9(5.0)	3(1.7)
	\$5,000-\$7,999 per month	6(3.3)	5(2.8)	4(2.2)	6(3.3)	6(3.3)	5(2.8)
	\$500-\$999 per month	28(15.6)	19(10.6)	14(7.8)	19(10.6)	19(10.6)	14(7.8)
	\$8,000-\$9,999 per month	4(2.2)	2(1.1)	2(1.1)	3(1.7)	3(1.7)	2(1.1)
	Less than \$500	78(43.3)	59(32.8)	40(22.2)	53(29.4)	62(34.4)	37(20.6)



**Fig. 1.** Nature of occupation of the respondents.

**Table 2.** Clinical updates on health status of the study participants (n=180).

Variable	Categories	Frequency	Percent
Diabetes	Don't know (never been tested or examined by a doctor)	38	21.1
	No (have been tested or examined by a doctor but negative)	127	70.6
	Yes (have been diagnosed by a doctor)	15	8.3
Heart disease	Don't know (never been tested or examined by a doctor)	38	21.1
	No (have been tested or examined by a doctor but negative)	138	76.7
	Yes (have been diagnosed by a doctor)	4	2.2
Pulmonary disease	Don't know (never been tested or examined by a doctor)	74	41.1
	No (have been tested or examined by a doctor but negative)	104	57.8
	Yes (have been diagnosed by a doctor)	2	1.1
Hypertension	Don't know (never been tested or examined by a doctor)	70	38.9
	No (have been tested or examined by a doctor but negative)	110	61.1

## DISCUSSION

In order to contain a pandemic, access to a potent and secure vaccine is a requirement for global public health. However, vaccination reluctance caused by worries about the effectiveness and safety can seriously delay immunization roll-out. A typical Nigerian who is worried about the immunization expresses fears about its side effects, probable mutations, disruptions of daily routine, and dread of mortality, among other things [14, 26].

This current study assessed willingness to receive the COVID-19 vaccination at different hypothetical efficacy and safety levels. Results indicate that the COVID-19 vaccine acceptance rate is inversely proportional to the age of the participants, which increases the acceptance rate to 27(15.0) 50% vaccine efficacy among those aged 41–50 years, 27(15.0) 75% vaccine efficacy among  $\leq 20$  years, 43(23.9) 75% vaccine efficacy among those aged 21–30 years, 38(21.1) 95% vaccine efficacy among those aged 31–40 years, and 9(5.0) at 95% vaccine efficacy among those above 51 years. According to a study by Syan *et al* [26], people's opinions of the safety and efficacy of the COVID-19 vaccine both changed with education and with age.

Willingness to accept the vaccine does not varied by age, but perceptions of vaccine safety does in line with our findings and in contrast to the submission of Olanipekun *et al* [27], who claimed that older age (>50 years) was associated with a higher vaccination rate. A higher acceptance rate of the COVID-19 vaccine among the aged may be because they are in the high-risk group for severe COVID-19 infection and adverse outcomes. Chances are that they may have received routine vaccinations against other illnesses like influenza and pneumonia and are aware of the advantages of immunization. Only 39.4% of the study participants who were healthcare professionals were willing to embrace the COVID-19 immunization according to Fojnica *et al* [28], while the rest were either hesitant or outright against it.

In this study, the gender of the respondents was significantly associated with COVID-19 vaccine acceptance at 50% vaccine efficacy 50% side effects. This was consistent with previous studies that had shown men are more likely to accept the COVID-19 vaccine [19, 29, 30]. According to research by Marzo *et al* [31], males were significantly more likely than females to agree that vaccines could effectively prevent and control COVID-19; the opinions of medical professionals and the cost of the vaccines in particular are crucial factors in deciding whether to accept COVID-19 vaccines or not.

People with heart disease, high blood pressure, or diabetes were considered more prone to developing a severe or fatal case of COVID-19, because SARS-CoV-2 interacts with its target cells through ACE-2 [32]. In this study, the clinical updates on the health status of the subjects show that less than one fifth of the total subjects know their current clinical updates on diabetes, heart disease, pulmonary disease, and hypertension even though more than one third (48.9%) of the respondents are health care workers, although all groups recognized almost the same fundamental facts about the illness, there were significant disparities in their awareness of the disease's impacts, high-risk demographics, personal safety measures, and therapy. The odd ratio of vaccine acceptance was high based on awareness of clinical status at 6.31, 0.24, 1.23, and 0.7 for diabetes, heart disease, pulmonary disease, and hypertension at 95% vaccine efficacy 5% side effects based on clinical status. This finding is corroborated by the submission of Pal *et al* [33], who reported there were gaps in their knowledge on COVID-19 and that the majority of patients were able to continue with their regular meals and therapies. Self-monitored capillary blood glucose readings, on the other hand, revealed that 72% of individuals had elevated blood sugar. This was most likely because the great majority of participants (almost 90%) reported being less active.

In this study, more than two thirds of the respondents were aware of social distancing, hand hygiene, using face masks, and avoiding traveling as some of the preventive measures against COVID-19, These are some the things that should be done to stop the disease from

spreading, which support the submission of Vincent and Taccone [34]; WHO [35], as well as Akther and Nur [36].

**Table 3.** Determinants associated with COVID-19 vaccine acceptance (n=180).

Variable	Categories	95% vaccine efficacy 5% side effect		50% vaccine efficacy 50% side effect		50% vaccine efficacy 5% side effect		75% vaccine efficacy 5% side effect		75% vaccine efficacy 20% side effect	
		P- value	OR(CL)	P- value	OR(CL)	P- value	OR	P- value	OR CI Lower Bound	P- value	OR
Age group (year)	≤20	0.974	0.962(0.10-9.54)	0.997	0.00(0.00- 0.00)	0.997	0.000(0.00-0.00)	0.995		0.997	0.000(0.00-0.00)
	21-30	0.891	0.861(0.10-7.40)	0.344	2.747(0.34-22.29)	0.649	0.586(0.05-5.83)	0.074	0.131(0.01-1.22)	0.822	0.800(0.11-5.60)
	31-40	0.745	0.689(0.07-6.55)	0.366	2.399(0.36-16.01)	0.549	1.907(0.23-15.73)	0.263	0.320(0.04-2.36)	0.730	1.367(0.23-8.06)
	41-50	0.917	0.890(0.10-5.33)	0.085	5.488(0.79-37.97)	0.871	1.199(0.13-10.64)	0.401	0.416(0.05-3.23)	0.816	1.241(0.20-7.67)
	>51			0.165	3.953(0.57-27.57)	0.811	1.313(0.14-12.21)	0.528	0.520(0.07-3.97)	0.847	0.833(0.13-5.30)
Gender	Female	0.193	1.949(0.71-5.33)	0.00	0.00(0.00-0.00)		(0.00-0.00)				
	Male			0.076	0.461(0.20-1.08)	0.862	1.079(0.46-2.54)	0.652	0.805(0.31-2.07)	0.370	0.697(0.32-1.53)
Location	Rural	0.449	1.795(0.39-3.73)	0.00	0.00(0.00-0.00)		(0.00-0.00)				0.000(0.00-0.00)
	Urban			0.156	0.361(0.09-1.48)	0.673	1.333(0.35-5.07)	0.948	1.052(0.23-4.83)	0.754	1.221(0.35-4.26)
Average income	\$1,000-\$1,999 per month	0.342	0.290(0.02-3.73)	0.00	0.00(0.00-0.00)		(0.00-0.00)				
	\$10,000-\$12,999 per month	0.122	10.509(0.54-206.53)	0.855	0.878(0.22-3.56)	0.219	0.321(0.05-1.96)	0.962	1.043(0.18-5.10)	0.238	2.288(0.58-9.05)
	\$13,000 per month or more	0.992	4.300(0.00-206.53)	0.993	9.5(0.00- 0.00)	0.384	3.419(0.22-54.46)	0.610	2.158(0.11-41.41)	0.652	1.866(0.12-28.15)
	\$2,000-\$2,999 per month	0.943	0.944(0.20-4.50)	0.715	0.700(0.10-4.77)	0.559	1.859(0.23-14.85)	0.318	3.026(0.34-26.60)	0.084	8.104(0.76-86.68)
	<b>Categories</b>	<b>95% vaccine efficacy 5% side effect</b>		<b>50% vaccine efficacy 50% side effect</b>		<b>50% vaccine efficacy 5% side effect</b>		<b>75% vaccine efficacy 5% side effect</b>		<b>75% vaccine efficacy 20% side effect</b>	
		P- value	OR(CL)	P- value	OR(CL)	P- value	OR	P- value	OR CI Lower Bound	P- value	OR
	\$3,000-\$4,999 per month	0.690	1.486(0.21-10.40)	0.906	0.924(0.248-3.446)	0.589	1.442(0.383-5.423)	0.817	0.841(0.195-3.624)	0.188	2.378(0.654-8.645)
	\$5,000-\$7,999 per month	0.841	1.301(0.10-16.92)	0.062	0.207(0.040-1.079)	0.164	3.054(0.635-14.691)	0.550	0.544(0.074-4.007)	0.300	2.359(0.465-11.957)
	\$500-\$999 per month	0.312	1.987(0.53-7.51)	0.206	0.238(0.026-2.204)	0.991	1.771(0.000-0.000)	0.992	2.366(0.000-0.000)	0.146	0.163(0.014-1.884)
	\$8,000-\$9,999 per month	0.973	0.959(0.09-10.84)	0.385	0.602(0.191-1.894)	0.744	1.214(0.379-3.886)	0.419	1.669(0.483-5.771)	0.999	1.001(0.337-2.969)
Religion	Catholic	0.997	4.54(0.00-0.00)	0.000	0.000(0.000-0.000)		(0.000-0.000)	0.000	0.000(0.000-0.000)	0.000	0.000(0.000-0.000)
	Christian/Protestant/Methodist/Lutheran/Baptist	0.997	5.66(0.00-0.00)	0.996	25.32(0.000- 0.00)	0.996	1.08(0.000-0.000)	0.997	3.4(0.000-0.000)	0.996	1.745(0.000-0.000)
	Muslim	0.997	31.145(0.00-0.00)	0.996	3.13(0.000- 0.00)	0.997	8.310(0.000-0.000)	0.997	0.87(0.000-0.000)	0.996	1.333(0.000-0.000)

			0.00)				0.000)		0.000 )		0.000)
	Other	0.000	0.000(0.00-0.00)	0.996	2.2(0.000- 0.00)	0.997	0.76(0.000-0.000)	0.997	0.45(0.000-0.000)	0.996	1.287(0.000-0.000)
Are you a healthcare worker (Nurse, Doctor, Laboratory Staff etc.)	No	0.187	0.00(0.18-1.40)	0.000	0.000(0.000-0.000)	0.000	0.000(0.000-0.000)	0.000	0.000 (0.000 - 0.000 )	0.000	0.000(0.000-0.000)
	Yes			0.386	0.696(0.307-1.579)	0.478	1.360(0.581-3.181)	0.233	0.556(0.212-1.459)	0.944	1.028(0.470-2.252)
<b>Variable</b>	<b>Categories</b>	<b>95% vaccine efficacy 5% side effect</b>		<b>50% vaccine efficacy 50% side effect</b>		<b>50% vaccine efficacy 5% side effect</b>		<b>75% vaccine efficacy 5% side effect</b>		<b>75% vaccine efficacy 20% side effect</b>	
		P-value	OR(CL)	P-value	OR(CL)	P-value	OR	P-value	OR CI Lower Bound	P-value	OR
Diabetes	Don't know	0.994	6.31(0.000-0.000)	0.00	0.00( 0.00- 0.00)	0.000	0.000(0.000-0.000)	0.000	0.000 (0.000 - 0.000 )	0.000	0.000(0.000-0.000)
	No	0.994	1.20(0.000-0.000)	0.993	1.42(0.000- 0.00)	0.993	3.41(0.000-0.000)	0.993	1.45(0.000-0.000 )	0.992	1.487(0.000-0.000)
	Yes	0.000	0.000(0.000-0.000)	0.992	5.10(0.000- 0.00)	0.993	2.82(0.000-0.000)	0.993	0.17(0.000-0.000 )	0.992	2.212(0.000-0.000)
Heart disease	Don't know	0.537	0.247(0.003-20.779)	0.00	0.00(0.00- 0.00)	0.000	0.000(0.000-0.000)	0.000	0.000 (0.000 - 0.000 )	0.000	0.000(0.000-0.000)
	No	0.494	0.221(0.003-16.807)	0.994	1.40(0.000- 0.00)	0.994	4.062(0.000-0.000)	0.979	1.052(0.022-50.722)	0.000	8.693(2.204-3.429)
	Yes	0.000	0.000(0.000-0.000)	0.994	2.14(0.000- 0.00)	0.994	3.86(0.000-0.000)	0.932	1.180(0.026-52.815)		2.084(2.084-2.084)
Pulmonary disease	No	0.825	1.233(0.193-7.860)	0.00	0.00( 0.00- 0.00)	0.000	0.000(0.000-0.000)	0.000	0.000 (0.000 - 0.000 )	0.000	0.000(0.000-0.000)
	Yes	0.000	0.000(0.000-0.000)	0.150	3.100(0.664-14.471)	0.974	0.975(0.207-4.589)	0.811	0.826(0.172-3.956)	0.115	3.131(0.759-12.923)
Hypertension	Don't know	0.790	0.696(0.048-10.047)	0.00	0.00( 0.00- 0.00)	0.000	0.000(0.000-0.000)	0.000	0.000 (0.000 - 0.000 )	0.000	0.000(0.000-0.000)
	No	0.746	0.678(0.065-7.071)	0.700	0.665(0.083-5.307)	0.629	1.814(0.162-20.350)	0.444	0.399(0.038-4.197)	0.944	0.933(0.134-6.476)
	Yes	0.000	0.000(0.000-0.000)	0.969	0.967(0.172-5.419)	0.410	2.437(0.293-20.297)	0.659	0.668(0.111-4.027)	0.992	0.991(0.196-5.001)
<b>Variable</b>	<b>Categories</b>	<b>95% vaccine efficacy 5% side effect</b>		<b>50% vaccine efficacy 50% side effect</b>		<b>50% vaccine efficacy 5% side effect</b>		<b>75% vaccine efficacy 5% side effect</b>		<b>75% vaccine efficacy 20% side effect</b>	
	<b>No</b>	<b>P-value</b>	<b>OR(CL)</b>	<b>P-value</b>	<b>OR(CL)</b>	<b>P-value</b>	<b>OR</b>	<b>P-value</b>	<b>OR CI Lower Bound</b>	<b>P-value</b>	<b>OR</b>
Did you wear a mask at work/school	Not applicable (not going out a whole week)	0.995	1.151(0.000-0.000)	0.054	0.146(0.021-1.030)	0.608	0.603(0.087-4.164)	0.810	1.290(0.162-10.251)	0.331	0.414(0.070-2.452)
	Yes, during my whole time at work/school	0.042	5.679(1.066-30.251)	0.855	0.749(0.034-16.593)	0.993	4.115(0.000-0.000)	0.912	1.207(0.044-33.363)	0.618	0.458(0.021-9.848)
	Yes, for part of the time at work/school	0.424	0.434(0.056-3.351)	0.030	0.177(0.037-0.842)	0.590	0.666(0.152-2.921)	0.789	0.788(0.137-4.534)	0.763	0.804(0.194-3.335)
In the past week, how often have you gone to a grocery store or	0 days	0.790	1.294(0.193-8.667)	0.134	0.315(0.069-1.429)	0.237	0.398(0.086-1.835)	0.563	0.595(0.103-3.449)	0.691	0.755(0.189-3.012)
	1 day	0.704	0.758(0.182-3.153)	0.017	0.135(0.026-0.701)	0.376	0.489(0.100-2.389)	0.568	0.561(0.077-4.074)	0.020	0.155(0.033-0.741)
	2 days	0.409	0.404(0.047-3.475)	0.261	0.518(0.164-1.633)	0.090	0.365(0.114-1.169)	0.263	0.476(0.130-1.746)	0.554	0.720(0.243-2.135)
	3 days			0.034	0.172(0.034-0.872)	0.370	0.499(0.109-2.283)	0.850	1.162(0.244-5.536)	0.350	0.509(0.124-2.098)
	4 days	0.996	59.800(0.000-0.000)	0.000	0.00(0.00-0.00)	0.000	0.000(0.000-0.000)			0.000	0.000(0.000-0.000)



other food vendor	5 days	0.892	0.848(0.078-9.273)	0.992	1.512(0.000-0.00)	0.993	4.092(0.000-0.000)	0.453	4.816(0.080-291.146)	0.991	6.637(0.000-0.000)
	6 days	0.348	1.696(0.563-5.113)	0.209	3.818(0.473-30.851)	0.525	0.501(0.060-4.212)	0.616	1.762(0.192-16.166)	0.794	1.294(0.188-8.924)
	7 days	0.000	0.000(0.000-0.000)	0.654	1.207(0.530-2.752)	0.205	0.566(0.235-1.365)	0.495	1.433(0.510-4.029)	0.178	0.573(0.255-1.288)
Did you wear a mask at the grocery store or other food vendor	No	0.000	4.601(1.311-1.615)	0.00	0.00(0.00-0.00)			0.000	0.000 (0.000 - 0.000 )	0.000	0.000(0.000-0.000)
	Not applicable (not going out to grocery store or other food vendor whole week)	0.993	3.890(0.000-0.000)	0.993	1.23(0.000-0.00)	0.994	1.11(0.000-0.000)	0.000	1.64(0.57-0.47)	0.993	2.432(0.000-0.000)
	Yes, during my whole time at the store	0.000	5.18(1.10-2.44)	0.993	61.000(0.000-0.00)	0.994	2.40(0.000-0.000)	0.995	2.123(0.000-0.000 )	0.993	1.905(0.000-0.000)
	Yes, for part of the time at the store	0.000	4.55(1.53-1.44)	0.993	8.1(0.000-0.00)	0.994	1.11(0.000-0.000)	0.000	1.913(0.47-0.77)	0.993	2.333(0.000-0.000)
Vaccines are important for my health	Agree			0.993	2.8(0.000-0.00)	0.994	1.01(0.000-0.000)	0.000	2.000(0.79-0.53)	0.993	2.766(0.000-0.000)
	Disagree	0.000	0.54(4.660000-19.88)	0.00	0.00(0.00-0.00)		(0.000-0.000)	0.000	0.000 (0.000 - 0.000 )	0.000	0.000(0.000-0.000)
	Neither agree nor disagree	0.994	1.550(0.000-0.000)	0.000	2.914(1.044-8.137)	0.000	4.161(1.44-1.199)	0.000	7.770(2.394-2.522)	0.000	1.562(5.984-4.077)
	Strongly agree	0.000	84.66(13.700-15.78)	0.986	3.598(0.000-0.00)	0.988	1.64(0.000-0.000)	0.994	2.095(0.000-0.000)	0.986	1.207(0.000-0.000)
	Strongly disagree	0.000	0.36(29.500-29.521)	0.000	3.738(7.899-1.769)	0.000	8.039(1.65-3.77)	0.000	6.924(1.079-4.444)	0.000	2.010(4.659-8.676)

## Strength and Limitation of the Study

The strength of this present study can be attributed to an analysis of the relationships between various COVID-19 vaccine safety and efficacy scenarios and intents to receive COVID-19 immunization on a national scale. On the other hand, the current study has inherent limitations, such as a small sample size, but the findings are supported by the discovery of comparable trends in COVID-19 vaccination acceptance rates compared to larger national studies. The possibility for sampling bias in favor of persons who are active users of social media platforms and who have reliable internet connection is another drawback of online survey studies.

## CONCLUSION

The findings from this study shows that the acceptance rate of COVID-19 vaccine among selected Nigeria population is inversely proportional to the age of the study participants, majority of respondents were aware of the knowledge, preventive measures and well prepared to fight against virus. It was evident that the respondent's clinical updates on the health status of the subjects were fairly satisfactory. This research demonstrates that knowledge and preparation improve the effectiveness of COVID-19 prevention practices. To totally eradicate COVID-19, it would be prudent to invest in various COVID-19 preventive interventions, such as health education and cutting-edge tactics based on local evidence, to improve public understanding of the disorder and improve health practices.

## CONSENT

All authors declared that informed consent was obtained from the participants with assurance of anonymity and confidentiality before the commencement of the study.

## ETHICS APPROVAL

This study was approved by the Institutional Review Board of the Universitas Syiah Kuala - Zainoel Abidin Hospital and National Health Research and Development Ethics Commission (KEPPKN) of the Ministry of Health of the Republic of Indonesia (#1171012P).

## ACKNOWLEDGMENTS

We are incredibly appreciative of the assistance from collators.

## CONFLICT OF INTEREST

The authors declare that they have no competing interests.

## FUNDING

This study was funded by Universitas Syiah Kuala (The Ministry of Education, Culture, Research, and Technology) - H-Index Research Scheme Financial Year 2021 (169/UN11/SPK/ PNBPN/2021).

## UNDERLYING DATA

Derived data supporting the findings of this study are available from the corresponding author [Seyi Samson Enitan] on request.

## REFERENCES

1. World Health Organization (WHO). Naming the coronavirus disease (COVID-19) and the virus that causes it. 2020. Available: [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it). Accessed: 30 May 2020.
2. Enitan SS, Ibeh IN, Oluremi AS, Olayanju AO, Itodo GE. The 2019 Novel Coronavirus Outbreak: Current Crises, Controversies and Global Strategies to Prevent a Pandemic. *International Journal of Pathogen Research*, 2020; 4(1): 1-16.
3. Patel A, Jernigan DB, 2019-nCoV CDC Response Team. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. *MMWR. Morbidity and mortality weekly report*, 2020; 69(5), 140–146. <https://doi.org/10.15585/mmwr.mm6905e1>.
4. Ibeh IN, Enitan SS, Akele RY, Isitua CC, Omorodion F. Global Impacts and Nigeria Responsiveness to the COVID-19 Pandemic. *International Journal of Healthcare and Medical Sciences*, 2020; 6(4): 27-45.
5. World Health Organization (WHO). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva: WHO; 2020. <https://www.who-china-joint-mission-on-covid-19-final-report.pdf> [Last accessed on Aug 22, 2022].
6. Okafor UG, Olalaye MA, Asobara HC, Umeodinka EF. Global impact of COVID-19 pandemic on public health supply chains. *IntechOpen*. 2021. <https://www.intechopen.com/chapters/76406>.
7. World Health Organization (WHO). WHO Coronavirus Disease 2019 (COVID-19) Dashboard. [Accessed on: 26 August 2021]. Available at: <https://covid19.who.int/>
8. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. *Nature reviews. Drug discovery*, 2020; 19(5), 305–306. <https://doi.org/10.1038/d41573-020-00073-5>.
9. Anderson EJ, Roupheal NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA, 2nd, Padilla M, Neuzil KM, ... mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *The New England journal of medicine*, 2020; 383(25): 2427–2438.
10. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD, Alden NB, Kawasaki B, Yousey-Hindes K, Niccolai L, Anderson EJ, Openo KP, Weigel A, Monroe ML, Ryan P, Henderson J, Kim S, ... Fry A. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR. Morbidity and mortality weekly report*, 2020; 69(15): 458–464.
11. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis *Aging*, 2020; 12(7): 6049–6057.

12. Garnier-Crussard A, Forestier E, Gilbert T, Krolak-Salmon P. Novel Coronavirus (COVID-19) Epidemic: What Are the Risks for Older Patients? *Journal of the American Geriatrics Society* 2020; 68(5): 939–940.
13. Yang R, Penders B, Horstman K. Addressing Vaccine Hesitancy in China: A Scoping Review of Chinese Scholarship. *Vaccines*, 2019; 8(1): 2. <https://doi.org/10.3390/vaccines8010002>.
14. Enitan SS, Oyekale AO, Akele RY, Olawuyi KA, Olabisi EO, Nwankiti AJ, Adejumo EN, Enitan CB. Assessment of knowledge, perception and readiness of Nigerians to participate in the covid-19 vaccine trial. *International Journal of Vaccines and Immunization*, 2020; 4(1): [dx.doi.org/10.16966/2470-9948.123](https://doi.org/10.16966/2470-9948.123).
15. Coe AB, Gatewood SB, Moczygemba LR, Goode JV, Beckner JO. The use of the health belief model to assess predictors of intent to receive the novel (2009) H1N1 influenza vaccine. *Innovations in pharmacy*, 2012; 3(2): 1–11.
16. Brewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, Weinstein ND. Meta-analysis of the relationship between risk perception and health behavior: the example of vaccination. *Health psychology: official journal of the Division of Health Psychology, American Psychological Association*, 2007; 26(2): 136–145.
17. Glanz K, Rimer BK, Viswanath K. Health behavior and health education: theory, research, and practice. 4th ed. San Francisco: John Wiley & Sons; 2008.
18. Nossier SA. Vaccine hesitancy: the greatest threat to COVID-19 vaccination programs. *The Journal of the Egyptian Public Health Association*, 2021; 96(1): 18.
19. Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. *Nature medicine*, 2021; 27(2): 225–228.
20. Paul E, Steptoe A, Fancourt D. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. *The Lancet regional health. Europe*, 2021; 1: 100012.
21. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. *Vaccines*, 2021; 9(2): 160.
22. Solís-Arce JS, Warren SS, Meriggi NF, Scacco A, McMurphy N, Voors M, Syunyaev G, Malik AA, Aboutajdine S, Adejo O, Anigo D, Armand A, Asad S, Atyera M, Augsburg B, Awasthi M, Ayesiga GE, Bancalari A, Björkman NM, Borisova E, ... Omer SB. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. *Nature medicine*, 2021; 27(8): 1385–1394.
23. Wagner A. COVID-19 Vaccine Hesitancy Surveys. In: Inter-university Consortium for Political and Social Research Available from: <https://doi.org/10.3886/E130422V2> 2021 (31 August 2021).
24. Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, Setiawan AM, Rajamoorthy Y, Sofyan H, Mudatsir M. Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. *Frontiers in public health*, 2020; 8: 381.
25. Akel KB, Masters NB, Shih SF, Lu Y, Wagner AL. Modification of a vaccine hesitancy scale for use in adult vaccinations in the United States and China. *Human vaccines & immunotherapeutics*, 2021; 17(8): 2639–2646.
26. Syan SK, Gohari MR, Levitt EE, Belisario K, Gillard J, DeJesus J, MacKillop J. COVID-19 Vaccine Perceptions and Differences by Sex, Age, and Education in 1,367 Community Adults in Ontario. *Frontiers in public health*, 2021; 9: 719665.
27. Olanipekun T, Effoe VS, Olanipekun O, Igbinomwanhia E, Kola-Kehinde O, Fotzeu C, Bakinde N, Harris R. Factors influencing the uptake of influenza vaccination in African American patients with heart failure: Findings from a large urban public hospital. *Heart & lung: the journal of critical care*, 2020; 49(3): 233–237.
28. Fojnica A, Osmanovic A, Đuzic N, Fejzic A, Mekic E, Gromilic Z, Muhovic I, Kurtovic-Kozaric A. COVID-19 vaccine acceptance and rejection in an adult population in Bosnia and Herzegovina. *PloS one*, 2022; 17(2): e0264754.
29. Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D, Yaseen A, Ababneh NA, Bakri FG, Mahafzah A. High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. *Vaccines*, 2021; 9(1): 42.
30. Wang K, Wong EL, Ho KF, Cheung AW, Yau PS, Dong D, Wong SY, Yeoh EK. Change of Willingness to Accept COVID-19 Vaccine

and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong, China: Repeated Cross-Sectional Surveys. *Vaccines*, 2021; 9(1), 62.

31. Marzo RR, Sami W, Alam MZ, Acharya S, Jermsittiparsert K, Songwathana K, Pham NT, Respati T, Faller EM, Baldonado AM, Aung Y, Borkar SM, Essar MY, Shrestha S, Yi S. Hesitancy in COVID-19 vaccine uptake and its associated factors among the general adult population: a cross-sectional study in six Southeast Asian countries. *Tropical medicine and health*, 2022; 50(1): 4.
32. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *The Lancet. Respiratory medicine*, 2020; 8(4): e21.
33. Pal R, Yadav U, Verma A, Bhadada SK. Awareness regarding COVID-19 and problems being faced by young adults with type 1 diabetes mellitus amid nationwide lockdown in India: A qualitative interview study. *Primary care diabetes*, 2021; 15(1): 10–15.
34. Vincent JL, Taccone FS. Understanding pathways to death in patients with COVID-19. *The Lancet. Respiratory medicine*, 2020; 8(5): 430–432.
35. World Health Organization (WHO). Coronavirus Disease 2019(COVID-19) Advice for the Public. 2020. Available online at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public> [Last accessed April 13, 2022].
36. Akther T, Nur T. A model of factors influencing COVID-19 vaccine acceptance: A synthesis of the theory of reasoned action, conspiracy theory belief, awareness, perceived usefulness, and perceived ease of use. *PLoS ONE*, 2022; 17(1): e0261869.